UCB News

UCB SA/NV Convertible Bond Early Redemption Option

Brussels (Belgium), January 16, 2014 – 8.30 p.m. (CET) – Regulated Information

UCB SA/NV (Euronext: UCB) (the "Company") announces that it decided today to make use of the early redemption option of the outstanding euro 500 million 4.50% Convertible Bonds due in 2015 (the "Bonds") as soon as and under the condition that the UCB share price exceeds the early redemption trigger as defined under Condition 6(b)(i) of the Terms & Conditions of the Bonds (the "Conditions").

Under this condition, UCB SA/NV is entitled to early redeem all outstanding Bonds on the Optional Redemption Date (as referred to in Condition 6(b)) at par together with interest accrued to that date as a result of the Parity Value having exceeded euro 65,000 on 20 out of 30 consecutive dealing days. As an alternative to the redemption of the Bonds, each Bondholder may exercise its conversion rights (the "Conversion Rights") in accordance with Condition 5(h) .

On 16 January 2014, the Parity Value exceeded euro 65,000 (as a result of daily volume weighted average prices (VWAP) having been above euro 50.37) on 18 out of 18 consecutive dealing days.

Words and expressions defined in the Conditions have the same meaning in this press release.

For further information

- Antje Witte, Investor Relations UCB
  T +32.2.559.9414, antje.witte@ucb.com
- Alexandra Deschner, Investor Relations, UCB
  T +32 2 559 9683, alexandra.deschner@ucb.com
- France Nivelle, Global Communications UCB
  T +32.2.559.9178, france.nivelle@ucb.com
- Laurent Schots, Media Relations, UCB
  T +32.2.559.9264, laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 9000 people in approximately 40 countries, the company generated revenue of EUR 3.4 billion in 2012. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly

disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.